American Society of Hematology

Session Previews

Focus on Leukemia
Speaker: Anjali Advani, MD

Anjali Advani, MD, and other expert speakers will discuss exciting updates in leukemia, including newly approved drugs (blinatumomab) and drugs in the pipeline (inotuzumab). Leukemia is one of the core malignancies that will be covered at the ASH Meeting on Hematologic Malignancies, which is structured in a “How I Treat” format that provides an ideal learning experience for physicians who treat leukemia. The meeting’s expert speakers will discuss specific patient cases, present cutting-edge scientific data, and provide insight into how new treatments can be incorporated upfront.

Focus on MDS 
Speaker: Amy DeZern, MD

Amy DeZern, MD, and other expert speakers will discuss exciting updates in myelodysplastic syndromes (MDS), including new drugs in the pipeline, such as targeted agents and spliceosome modulators. MDS is one of the core malignancies that will be covered at the ASH Meeting on Hematologic Malignancies. During the meeting, experts will take true clinical scenarios and offer insight into how novel testing and the novel potential therapeutic pathways can be incorporated to improve diagnosis and treatment.

Focus on Lymphoma 
Speaker: John Leonard, MD, and Jonathan Friedberg, MD, MMSc

John P. Leonard, MD, Jonathan W. Friedberg, MD, and other expert speakers will discuss exciting updates in lymphoma, including newly approved drugs (e.g., obinutuzumab for chronic lymphocytic leukemia) and new data that may have practice-changing implications for various lymphoma subtypes. Lymphoma is one of the core malignancies that will be covered at the ASH Meeting on Hematologic Malignancies. The meeting will focus not only on what the data show but on how to apply the data to optimally treat patients. The meeting will also feature a talk that focuses on which tests to run to diagnose and follow patients across the non-Hodgkin lymphoma spectrum.

Focus on MPN
Speaker: Ruben Mesa, MD

Ruben A. Mesa, MD, and other expert speakers will discuss exciting updates in myeloproliferative neoplasms (MPN), including new JAK-2 inhibitors that might influence treatment and the emergence of precision medicine. MPN is one of the core malignancies that will be covered at the ASH Meeting on Hematologic Malignancies. The meeting’s expert speakers will discuss challenging patient cases, present new data, and provide insight into how physicians can apply new treatments to patients the very next day.

Focus on Myeloma
Speaker: S. Vincent Rajkumar, MD

S. Vincent Rajkumar, MD, and other expert speakers will discuss exciting advances in myeloma, including new drugs in the pipeline (e.g., selinexor and venetoclax). Myeloma is one of the core malignancies that will be covered at the ASH Meeting on Hematologic Malignancies, a practical and practice-focused meeting that offers an ideal learning experience for physicians who treat myeloma and other hematologic malignancies.

back to top